The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Prospects for the use of NK cells in immunotherapy of human cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Lanier, L. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,769
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687 · cited 1×
“, a phenomenon referred to as 'missing-self' recognitio”
BackgroundSelf-citationRosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
Braud, V. M., Allan, D. S. J., O'Callaghan, C. A., Söderström, K., D'Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., et al. (1998) · Nature · doi:10.1038/35869 · Cited by 2,227
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Self-citationNATURAL KILLER CELLS IN ANTIVIRAL DEFENSE: Function and Regulation by Innate Cytokines
Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., & Salazar-Mather, T. P. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.189 · Cited by 2,113
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Kiessling, R., Klein, E., & Wigzell, H. (1975) · European Journal of Immunology · doi:10.1002/eji.1830050208 · Cited by 1,824
Kolb, H., Mittermuller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M., & Wilmanns, W. (1990) · Blood · doi:10.1182/blood.v76.12.2462.2462 · Cited by 1,528
Herberman, R. B., Nunn, M. E., & Lavrin, D. H. (1975) · International Journal of Cancer · doi:10.1002/ijc.2910160204 · Cited by 1,355
Licensing of natural killer cells by host major histocompatibility complex class I molecules
Kim, S., Poursine-Laurent, J., Truscott, S. M., Lybarger, L., Song, Y.-J., Yang, L., French, A. R., Sunwoo, J. B., Lemieux, S., Hansen, T. H., et al. (2005) · Nature · doi:10.1038/nature03847 · Cited by 1,340
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H. (2005) · Nature · doi:10.1038/nature03884 · Cited by 1,308
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232
Human NK Cell Education by Inhibitory Receptors for MHC Class I
Anfossi, N., André, P., Guia, S., Falk, C. S., Roetynck, S., Stewart, C. A., Breso, V., Frassati, C., Reviron, D., Middleton, D., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.013 · Cited by 1,211
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., & Emerson, S. G. (1999) · Science · doi:10.1126/science.285.5426.412 · Cited by 1,186
Aversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391702 · Cited by 1,168
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999) · Blood · doi:10.1182/blood.v94.1.333.413a31_333_339 · Cited by 994
Gattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 958
Colonna, M., Navarro, F., Bellón, T., Llano, M., García, P., Samaridis, J., Angman, L., Cella, M., & López-Botet, M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.11.1809 · Cited by 950
Ghiringhelli, F., Ménard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B., Vivier, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 949
Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B., Cantoni, C., Grassi, J., Marcenaro, S., Reymond, N., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030788 · Cited by 875
Imprint of human cytomegalovirus infection on the NK cell receptor repertoire
Gumá, M., Angulo, A., Vilches, C., Gómez-Lozano, N., Malats, N., & López-Botet, M. (2004) · Blood · doi:10.1182/blood-2004-05-2058 · Cited by 865
Bryceson, Y. T., March, M. E., Ljunggren, H.-G., & Long, E. O. (2006) · Blood · doi:10.1182/blood-2005-04-1351 · Cited by 863
Self-citationAdoptive immunotherapy for cancer: building on success
Gattinoni, L., Powell, D. J., Rosenberg, S. A., & Restifo, N. P. (2006) · Nature Reviews Immunology · doi:10.1038/nri1842 · Cited by 845
Pende, D., Parolini, S., Pessino, A., Sivori, S., Augugliaro, R., Morelli, L., Marcenaro, E., Accame, L., Malaspina, A., Biassoni, R., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1505 · Cited by 798
Vitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R., Moretta, L., & Moretta, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2065 · Cited by 748
Ljunggren, H. G., & Kärre, K. (1985) · The Journal of experimental medicine · doi:10.1084/jem.162.6.1745 · Cited by 736
Self-citationRajagopalan, S., & Long, E. O. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.7.1093 · Cited by 726
Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R., Bottino, C., Moretta, L., & Moretta, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730640100 · Cited by 726
A Novel Immunoglobulin Superfamily Receptor for Cellular and Viral MHC Class I Molecules
Cosman, D., Fanger, N., Borges, L., Kubin, M., Chin, W., Peterson, L., & Hsu, M.-L. (1997) · Immunity · doi:10.1016/s1074-7613(00)80529-4 · Cited by 695
Interleukin-12 in anti-tumor immunity and immunotherapy
Colombo, M. P., & Trinchieri, G. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00032-6 · Cited by 685
Imai, C., Iwamoto, S., & Campana, D. (2005) · Blood · doi:10.1182/blood-2004-12-4797 · Cited by 659
Activation, coactivation, and costimulation of resting human natural killer cells
Bryceson, Y. T., March, M. E., Ljunggren, H., & Long, E. O. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00457.x · Cited by 650
Self-citationIn vivo imaging platform for tracking immunotherapeutic cells
Ahrens, E. T., Flores, R., Xu, H., & Morel, P. A. (2005) · Nature Biotechnology · doi:10.1038/nbt1121 · Cited by 620
Unravelling natural killer cell function: triggering and inhibitory human NK receptors
Moretta, L., & Moretta, A. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600019 · Cited by 615
Fernandez, N. C., Treiner, E., Vance, R. E., Jamieson, A. M., Lemieux, S., & Raulet, D. H. (2005) · Blood · doi:10.1182/blood-2004-08-3156 · Cited by 588
Pessino, A., Sivori, S., Bottino, C., Malaspina, A., Morelli, L., Moretta, L., Biassoni, R., & Moretta, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.5.953 · Cited by 579
Giebel, S. (2003) · Blood · doi:10.1182/blood-2003-01-0091 · Cited by 549
Moretta, A., Vitale, M., Bottino, C., Orengo, A. M., Morelli, L., Augugliaro, R., Barbaresi, M., Ciccone, E., & Moretta, L. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.597 · Cited by 534
Human natural killer cell development and biology
Farag, S. S., & Caligiuri, M. A. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.10.001 · Cited by 506
What does it take to make a natural killer?
Colucci, F., Caligiuri, M. A., & Di Santo, J. P. (2003) · Nature Reviews Immunology · doi:10.1038/nri1088 · Cited by 493
Hsu, K. C., Keever-Taylor, C. A., Wilton, A., Pinto, C., Heller, G., Arkun, K., O'Reilly, R. J., Horowitz, M. M., & Dupont, B. (2005) · Blood · doi:10.1182/blood-2004-12-4825 · Cited by 473
The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3
Selvaraj, P., Plunkett, M. L., Dustin, M., Sanders, M. E., Shaw, S., & Springer, T. A. (1987) · Nature · doi:10.1038/326400a0 · Cited by 442
Natural Killer Cells and Cancer
(2003) · Advances in Cancer Research · doi:10.1016/s0065-230x(03)90004-2 · Cited by 438
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2862 · Cited by 434
Determinants of Antileukemia Effects of Allogeneic NK Cells
Leung, W., Iyengar, R., Turner, V., Lang, P., Bader, P., Conn, P., Niethammer, D., & Handgretinger, R. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.644 · Cited by 425
Winter, C. C., Gumperz, J. E., Parham, P., Long, E. O., & Wagtmann, N. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.571 · Cited by 422
2B4, the Natural Killer and T Cell Immunoglobulin Superfamily Surface Protein, Is a Ligand for CD48
Brown, M. H., Boles, K., Anton van der Merwe, P., Kumar, V., Mathew, P. A., & Neil Barclay, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2083 · Cited by 415
Interplay of natural killer cells and their receptors with the adaptive immune response
Raulet, D. H. (2004) · Nature Immunology · doi:10.1038/ni1114 · Cited by 413
Cytokines in cancer immunity and immunotherapy
Smyth, M. J., Cretney, E., Kershaw, M. H., & Hayakawa, Y. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00199.x · Cited by 412
Killer immunoglobulin-like receptors
Moretta, L., & Moretta, A. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.07.010 · Cited by 409
Recognition of peptide–MHC class I complexes by activating killer immunoglobulin-like receptors
Stewart, C. A., Laugier-Anfossi, F., Vély, F., Saulquin, X., Riedmuller, J., Tisserant, A., Gauthier, L., Romagné, F., Ferracci, G., Arosa, F. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503594102 · Cited by 406
Chiesa, M. D., Carlomagno, S., Frumento, G., Balsamo, M., Cantoni, C., Conte, R., Moretta, L., Moretta, A., & Vitale, M. (2006) · Blood · doi:10.1182/blood-2006-03-006700 · Cited by 399
Moretta, A., Bottino, C., Pende, D., Tripodi, G., Tambussi, G., Viale, O., Orengo, A., Barbaresi, M., Merli, A., & Ciccone, E. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.6.1589 · Cited by 385
Pende, D., Spaggiari, G. M., Marcenaro, S., Martini, S., Rivera, P., Capobianco, A., Falco, M., Lanino, E., Pierri, I., Zambello, R., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3548 · Cited by 374
Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants
Davies, S. M., Ruggieri, L., DeFor, T., Wagner, J. E., Weisdorf, D. J., Miller, J. S., Velardi, A., & Blazar, B. R. (2002) · Blood · doi:10.1182/blood-2002-04-1197 · Cited by 368
Anegón, I., Cuturi, M. C., Trinchieri, G., & Perussia, B. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.2.452 · Cited by 368
Pende, D., Biassoni, R., Cantoni, C., Verdiani, S., Falco, M., di Donato, C., Accame, L., Bottino, C., Moretta, A., & Moretta, L. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.505 · Cited by 365
Fuchs, A., Cella, M., Giurisato, E., Shaw, A. S., & Colonna, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.3994 · Cited by 358
Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?
Muranski, P., Boni, A., Wrzesinski, C., Citrin, D. E., Rosenberg, S. A., Childs, R., & Restifo, N. P. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0666 · Cited by 358
A human killer inhibitory receptor specific for HLA-A1,2
Döhring, C., Scheidegger, D., Samaridis, J., Cella, M., & Colonna, M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.9.3098 · Cited by 349
Cella, M., Longo, A., Ferrara, G. B., Strominger, J. L., & Colonna, M. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1235 · Cited by 340
Interleukin-2, Interleukin-15, and Their Roles in Human Natural Killer Cells
Becknell, B., & Caligiuri, M. A. (2005) · Advances in Immunology · doi:10.1016/s0065-2776(04)86006-1 · Cited by 325
Hayashi, T., Hideshima, T., Akiyama, M., Podar, K., Yasui, H., Raje, N., Kumar, S., Chauhan, D., Treon, S. P., Richardson, P., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05286.x · Cited by 323
Recognition of HLA‐A3 and HLA‐A11 by KIR3DL2 is peptide‐specific
Hansasuta, P., Dong, T., Thananchai, H., Weekes, M., Willberg, C., Aldemir, H., Rowland‐Jones, S., & Braud, V. M. (2004) · European Journal of Immunology · doi:10.1002/eji.200425089 · Cited by 318
Bottino, C., Falco, M., Parolini, S., Marcenaro, E., Augugliaro, R., Sivori, S., Landi, E., Biassoni, R., Notarangelo, L. D., Moretta, L., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.3.235 · Cited by 310
Miller, J. S., Cooley, S., Parham, P., Farag, S. S., Verneris, M. R., McQueen, K. L., Guethlein, L. A., Trachtenberg, E. A., Haagenson, M., Horowitz, M. M., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065383 · Cited by 288
Cutting Edge: Lectin-Like Transcript-1 Is a Ligand for the Inhibitory Human NKR-P1A Receptor
Rosen, D. B., Bettadapura, J., Alsharifi, M., Mathew, P. A., Warren, H. S., & Lanier, L. L. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.7796 · Cited by 288
Cutting Edge: Lectin-Like Transcript 1 Is a Ligand for the CD161 Receptor
Aldemir, H., Prod’homme, V., Dumaurier, M.-J., Retiere, C., Poupon, G., Cazareth, J., Bihl, F., & Braud, V. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.7791 · Cited by 285
Surface NK receptors and their ligands on tumor cells
Moretta, L., Bottino, C., Pende, D., Castriconi, R., Mingari, M. C., & Moretta, A. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.03.002 · Cited by 283
Interleukin-2 and interleukin-15: immunotherapy for cancer
Fehniger, T. A., Cooper, M. A., & Caligiuri, M. A. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00021-1 · Cited by 280
Passweg, J. R., Tichelli, A., Meyer-Monard, S., Heim, D., Stern, M., Kühne, T., Favre, G., & Gratwohl, A. (2004) · Leukemia · doi:10.1038/sj.leu.2403524 · Cited by 270
Uherek, C., Tonn, T., Uherek, B., Becker, S., Schnierle, B., Klingemann, H.-G., & Wels, W. (2002) · Blood · doi:10.1182/blood.v100.4.1265.h81602001265_1265_1273 · Cited by 262
Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction
Welte, S., Kuttruff, S., Waldhauer, I., & Steinle, A. (2006) · Nature Immunology · doi:10.1038/ni1402 · Cited by 260
Ito, M., Maruyama, T., Saito, N., Koganei, S., Yamamoto, K., & Matsumoto, N. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051986 · Cited by 260
Licensing of natural killer cells by self‐major histocompatibility complex class I
Yokoyama, W. M., & Kim, S. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00458.x · Cited by 259
Skov, S., Pedersen, M. T., Andresen, L., Thor Straten, P., Woetmann, A., & Ødum, N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0599 · Cited by 259
Natural Killer Cell-Mediated Killing of Freshly Isolated Neuroblastoma Cells
Castriconi, R., Dondero, A., Corrias, M. V., Lanino, E., Pende, D., Moretta, L., Bottino, C., & Moretta, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2682 · Cited by 259
Shilling, H. G., McQueen, K. L., Cheng, N. W., Shizuru, J. A., Negrin, R. S., & Parham, P. (2003) · Blood · doi:10.1182/blood-2002-08-2568 · Cited by 257
Cellular ligands of activating NK receptors
Bottino, C., Castriconi, R., Moretta, L., & Moretta, A. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.02.007 · Cited by 255
Nicoll, G., Ni, J., Liu, D., Klenerman, P., Munday, J., Dubock, S., Mattei, M.-G., & Crocker, P. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.48.34089 · Cited by 253
Burns, L. J., Weisdorf, D. J., DeFor, T. E., Vesole, D. H., Repka, T. L., Blazar, B. R., Burger, S. R., Panoskaltsis-Mortari, A., Keever-Taylor, C. A., Zhang, M.-J., et al. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704086 · Cited by 252
Moretta, A., Tambussi, G., Bottino, C., Tripodi, G., Merli, A., Ciccone, E., Pantaleo, G., & Moretta, L. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.171.3.695 · Cited by 250
Farag, S. S., Bacigalupo, A., Eapen, M., Hurley, C., Dupont, B., Caligiuri, M. A., Boudreau, C., Nelson, G., Oudshoorn, M., van Rood, J., et al. (2006) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2006.05.007 · Cited by 243
Carlsten, M., Björkström, N. K., Norell, H., Bryceson, Y., van Hall, T., Baumann, B. C., Hanson, M., Schedvins, K., Kiessling, R., Ljunggren, H.-G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2264 · Cited by 234
Self-citationActivation and self‐tolerance of natural killer cells
Gasser, S., & Raulet, D. H. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00460.x · Cited by 233
Sayers, T. J., Brooks, A. D., Koh, C. Y., Ma, W., Seki, N., Raziuddin, A., Blazar, B. R., Zhang, X., Elliott, P. J., & Murphy, W. J. (2003) · Blood · doi:10.1182/blood-2002-09-2975 · Cited by 227
Cooley, S., Xiao, F., Pitt, M., Gleason, M., McCullar, V., Bergemann, T. L., McQueen, K. L., Guethlein, L. A., Parham, P., & Miller, J. S. (2007) · Blood · doi:10.1182/blood-2006-07-036228 · Cited by 226
NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity
Albertsson, P. A., Basse, P. H., Hokland, M., Goldfarb, R. H., Nagelkerke, J. F., Nannmark, U., & Kuppen, P. J. K. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.09.007 · Cited by 226
Identification of NKp80, a novel triggering molecule expressed by human NK cells
Vitale, M., Falco, M., Castriconi, R., Parolini, S., Zambello, R., Semenzato, G., Biassoni, R., Bottino, C., Moretta, L., & Moretta, A. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200101)31:1<233::aid-immu233>3.0.co;2-4 · Cited by 223
Biassoni, R., Pessino, A., Malaspina, A., Cantoni, C., Bottino, C., Sivori, S., Moretta, L., & Moretta, A. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271203 · Cited by 213
NK cells are essential for effective BCG immunotherapy
Brandau, S., Riemensberger, J., Jacobsen, M., Kemp, D., Zhao, W., Zhao, X., Jocham, D., Ratliff, T. L., & B�hle, A. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010601)92:5<697::aid-ijc1245>3.0.co;2-z · Cited by 212
Immunobiology of Human NKG2D and Its Ligands
González, S., Groh, V., & Spies, T. (2006) · Current Topics in Microbiology and Immunology · doi:10.1007/3-540-27743-9_6 · Cited by 211
Cooley, S., McCullar, V., Wangen, R., Bergemann, T. L., Spellman, S., Weisdorf, D. J., & Miller, J. S. (2005) · Blood · doi:10.1182/blood-2005-04-1644 · Cited by 207
Cutting Edge: Identification of the 2B4 Molecule as a Counter-Receptor for CD48
Latchman, Y. E., McKay, P. F., & Reiser, H. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.11.5809 · Cited by 180
Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors
Valés-Gómez, M., Reyburn, H. T., Erskine, R. A., & Strominger, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14326 · Cited by 175
NATURAL KILLER CELLS IN THE MOUSE
Kiessling, R. W. (1976) · Elsevier eBooks · doi:10.1016/b978-0-12-401660-6.50012-6 · Cited by 173
Beelen, D. W., Ottinger, H. D., Ferencik, S., Elmaagacli, A. H., Peceny, R., Trenschel, R., & Grosse-Wilde, H. (2005) · Blood · doi:10.1182/blood-2004-04-1441 · Cited by 172
Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self
Ruggeri, L., Aversa, F., Martelli, M. F., & Velardi, A. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00455.x · Cited by 172
Colonna, M., Spies, T. A., Strominger, J. L., Ciccone, E., Moretta, A., Moretta, L., Pende, D., & Viale, O. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.17.7983 · Cited by 170
Identification of the 2B4 molecule as a counter-receptor for CD48.
Latchman, Y. E., McKay, P. F., & Reiser, H. (1998) · PubMed · Cited by 170
Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma
Gluck, W. L., Hurst, D., Yuen, A., Levine, A. M., Dayton, M. A., Gockerman, J. P., Lucas, J., Denis-Mize, K., Tong, B., Navis, D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1087-3 · Cited by 166
Functional Polymorphism of the KIR3DL1/S1 Receptor on Human NK Cells
O’Connor, G. M., Guinan, K. J., Cunningham, R. T., Middleton, D., Parham, P., & Gardiner, C. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.235 · Cited by 162
Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo
Koh, C. Y., Blazar, B. R., George, T., Welniak, L. A., Capitini, C. M., Raziuddin, A., Murphy, W. J., & Bennett, M. (2001) · Blood · doi:10.1182/blood.v97.10.3132 · Cited by 160
Link, B. K., Ballas, Z. K., Weisdorf, D. J., Wooldridge, J. E., Bossler, A., Shannon, M., Rasmussen, W. L., Krieg, A. Μ., & Weiner, G. J. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211304.60126.8f · Cited by 153
Tarn, Y. K., Martinson, J., Doligosa, K., & Klingernann, H.-G. (2003) · Cytotherapy · doi:10.1080/14653240310001523 · Cited by 149
Carr, W. H., Rosen, D. B., Arase, H., Nixon, D. F., Michaëlsson, J., & Lanier, L. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.2.647 · Cited by 149
Bouteiller, P. P. L., Barakonyi, A., Giustiniani, J., Lenfant, F., Marie‐Cardine, A., Aguerre‐Girr, M., Rabot, M., Hilgert, I., Mami‐Chouaib, F., Tabiasco, J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012681099 · Cited by 146
Lundqvist, A., Abrams, S. I., Schrump, D. S., Alvarez, G., Suffredini, D. A., Berg, M., & Childs, R. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0680 · Cited by 145
A new method for in vitro expansion of cytotoxic human CD3−CD56+ natural killer cells
Carlens, S., Gilljam, M., Chambers, B. J., ASCHAN, J., Guvén, H., Ljunggren, H., Christensson, B., & Dilber, M. S. (2001) · Human Immunology · doi:10.1016/s0198-8859(01)00313-5 · Cited by 144
Self-citationRole of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors
Bornhäuser, M., Schwerdtfeger, R., Martin, H., Frank, K., Theuser, C., & Ehninger, G. (2004) · Blood · doi:10.1182/blood-2003-11-3893 · Cited by 140
The DNA damage response, immunity and cancer
Gasser, S., & Raulet, D. H. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.004 · Cited by 136
Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer.
Ruggeri, L., Mancusi, A., Capanni, M., Martelli, M., & Velardi, A. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.01.007 · Cited by 128
Zhang, T., Barber, A., & Sentman, C. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0130 · Cited by 128
Shahied, L., Tang, Y., Alpaugh, R. K., Somer, R. A., Greenspon, D., & Weiner, L. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407888200 · Cited by 120
Ex vivo expansion of natural killer cells for clinical applications
Klingemann, H.-G., & Martinson, J. (2004) · Cytotherapy · doi:10.1080/14653240310004548 · Cited by 117
Soiffer, R. J., Alyea, E. P., Hochberg, E. P., Wu, C. J., Canning, C. M., Parikh, B., Zahrieh, D., Webb, I. J., Antin, J. H., & Ritz, J. (2002) · Transplantation and Cellular Therapy · doi:10.1053/bbmt.2002.v8.abbmt080625 · Cited by 113
Trafficking of Natural Killer Cells
MORRIS, M. A., & Ley, K. F. (2004) · Current Molecular Medicine · doi:10.2174/1566524043360609 · Cited by 101
Hartmann, F., Renner, C., Jung, W. E., Costa, L. M. D., Tembrink, S., Held, G., Sek, A., König, J., Bauer, S., Kloft, M., et al. (2001) · PubMed · Cited by 99
Schaffer, M., Malmberg, K., Ringdén, O., Ljunggren, H., & Remberger, M. (2004) · Transplantation · doi:10.1097/01.tp.0000137103.19717.86 · Cited by 95
Self-citationInterleukin-2 and the development of immunotherapy for the treatment of patients with cancer.
Rosenberg, S. A. (2000) · PubMed · Cited by 93
Lundqvist, A., McCoy, J. P., Samsel, L., & Childs, R. W. (2006) · Blood · doi:10.1182/blood-2006-05-024315 · Cited by 91
Cutting Edge: NTB-A Activates NK Cells via Homophilic Interaction
Flaig, R. M., Stark, S., & Watzl, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.6524 · Cited by 86
Use of natural killer cells in hematopoetic stem cell transplantation
Passweg, J. R., Stern, M., Koehl, U., Uharek, L., & Tichelli, A. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704810 · Cited by 84
Innate Immune Recognition and Suppression of Tumors
Hayakawa, Y., & Smyth, M. J. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)95008-8 · Cited by 76
Escape from immune- and nonimmune-mediated tumor surveillance.
Malmberg, K., & Ljunggren, H. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.007 · Cited by 76
Self-citationNatural killer cell-based immunotherapeutic strategies
Klingemann, H.-G. (2005) · Cytotherapy · doi:10.1016/s1465-3249(05)70785-4 · Cited by 73
Butcher, S., Arney, K. L., & Cook, G. P. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199811)28:11<3755::aid-immu3755>3.0.co;2-3 · Cited by 68
Bruenke, J., Barbin, K., Kunert, S., Lang, P., Pfeiffer, M. M., Stieglmaier, K., NIETHAMMER, D., Stockmeyer, B., Peipp, M., Repp, R., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05414.x · Cited by 63
VanOosten, R. L., Moore, J. M., Karaçay, B., & Griffith, T. S. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.10.2022 · Cited by 60
In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides
Fujii, H., Trudeau, J. D., Teachey, D. T., Fish, J. D., Grupp, S. A., Schultz, K. R., & Reid, G. S. D. (2006) · Blood · doi:10.1182/blood-2006-02-002055 · Cited by 41
Koh, C., Ortaldo, J., Blazar, B., Bennett, M., & Murphy, W. (2003) · Blood · doi:10.1182/blood-2003-04-1367 · Cited by 40
Cytokine Modulation of the Innate Immune System in the Treatment of Leukemia and Lymphoma
Farag, S. S., & Caligiuri, M. A. (2004) · Advances in pharmacology · doi:10.1016/s1054-3589(04)51013-x · Cited by 34
Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma
Curti, B. D. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.6.905 · Cited by 34
Cited by
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
Innate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT
Malladi, S., Macalinao, D. G., Jin, X., He, L., Basnet, H., Zou, Y., de Stanchina, E., & Massagué, J. (2016) · Cell · doi:10.1016/j.cell.2016.02.025 · Cited by 791
Cytokine activation induces human memory-like NK cells
Romee, R., Schneider, S. E., Leong, J. W., Chase, J. M., Keppel, C. R., Sullivan, R. P., Cooper, M. A., & Fehniger, T. A. (2012) · Blood · doi:10.1182/blood-2012-04-419283 · Cited by 684
Metadata
- Authors
- Ljunggren, H.-G., & Malmberg, K.-J.
- Venue
- Nature Reviews Immunology
- Published
- 2007-05
- Volume
- 7
- Issue
- 5
- Pages
- 329-339
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2063022052
- Cited by
- 543
- References
- 142
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.